Generation Bio Co GBIO.OQ GBIO.O is expected to show a fall in quarterly revenue when it reports results on November 4 (estimated) for the period ending September 30 2025
The Cambridge Massachusetts-based company is expected to report a 91.3% decrease in revenue to $660 thousand from $7.55 million a year ago, according to the mean estimate from 5 analysts, based on LSEG data.
LSEG's mean analyst estimate for Generation Bio Co is for a loss of $3.17 per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," 3 "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Generation Bio Co is $13.50, about 59.3% above its last closing price of $5.50
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Jun. 30 2025 | -2.73 | -2.85 | -3.12 | Missed | -9.5 |
Mar. 31 2025 | -2.98 | -2.93 | -2.20 | Beat | 25 |
Dec. 31 2024 | -2.96 | -3.01 | -3.20 | Missed | -6.2 |
Sep. 30 2024 | -2.80 | -2.83 | -2.30 | Beat | 18.6 |
Jun. 30 2024 | -2.89 | -2.78 | -3.10 | Missed | -11.3 |
Mar. 31 2024 | -4.02 | -4.08 | -11.20 | Missed | -174.4 |
Dec. 31 2023 | -4.39 | -4.49 | -5.30 | Missed | -18.2 |
Sep. 30 2023 | -5.03 | -5.05 | -4.30 | Beat | 14.9 |
This summary was machine generated October 31 at 23:42 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)